Status:
TERMINATED
Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
Lead Sponsor:
Pioneer Surgical Technology, Inc.
Conditions:
Degenerative Disc Disease
Spinal Stenosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most wi...
Detailed Description
The post marketing clinical trial is designed to assess lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone vo...
Eligibility Criteria
Inclusion
- The patient can be included in the study if all of the following criteria are met;
- is at least 18 years of age and skeletally mature
- must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc disease (DDD) at one or two adjacent levels from L2-S1 requiring a fusion
- must have completed a minimum of three months of unsuccessful conservative, non-operative care
- must have discogenic back pain with or without leg pain
- DDD must be confirmed by MRI or CT scans followed by discography (if necessary)
- must score at least 40 points on the Oswestry Disability Index
- must score at least a 4 on a 10 cm Visual Analog Scale for back pain
- must be able to comply with the protocol"s follow-up schedule
- must understand and sign the informed consent document
Exclusion
- The patient must not exhibit any of the following criteria;
- symptomatic at more than two levels
- previous fusion surgery at any lumbar level with or without instrumentation (prior discectomy, laminotomy, laminectomy or nucleolysis at the operative (involved) level \> 6 months is permitted)
- more than 50% spondylolisthesis
- lumbar scoliosis greater than 11 degrees
- osteoporosis\*, osteopenia, osteomalacia, Paget"s disease or metabolic bone disease.
- spinal tumors
- active arachnoiditis Pioneer Surgical Technology Confidential nanOss Bioactive Post Marketing Clinical Study: March 11, 2010 Page 8
- fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
- Impaired calcium metabolism
- active infection or surgical site infection
- rheumatoid arthritis or other autoimmune disease
- chronic steroid use (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing
- systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis
- morbid obesity defined as body mass index (BMI) \>40 or a weight more than 100 lbs over ideal body weight
- smokers unless the patient agrees to quit at least 2 weeks prior to and for the duration of the study, confirmed by a carboxyhemoglobin test prior to surgery
- psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse
- active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years
- documented allergies to porcine collagen or titanium
- pregnancy, or interested in becoming pregnant in the next four years
- participation in another investigational study within 30 days \*Osteoporosis will be assessed at the time of the preoperative evaluation based on the patient"s history, physical examination and review of the radiographic evaluations. All patients at risk for osteoporosis must obtain a DEXA scan of the spine and hip to determine if the patient has severe osteoporosis. The definition of a patient at risk used by the National Osteoporosis Foundation includes the following: i. Premature menopause (\< 45 years) ii. Prolonged amenorrhea (\> one year) iii. Maternal history of hip fracture iv. Primary hyperparathyroidism or hyperthyroidism v. Chronic renal failure vi. Previous fragility fractures, particularly of the hip, spine or wrist vii. Patients who have ever taken corticosteroids in doses \>7.5 mg/day for one year or more. Patients will be excluded if their bone mineral density (BMD) in the spine or hip is more than 1.0 standard deviation (SD) below the mean of normal adults in the presence of one or more fragility fractures indicating severe osteoporosis. If severe osteoporosis is diagnosed, the patient must be excluded from the investigational study. If the patient has osteoporosis or osteopenia, they may be included in the study if he or she meets the rest of the inclusion and exclusion criteria.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01452516
Start Date
July 1 2010
End Date
September 1 2013
Last Update
December 7 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Tower Orthopaedics & Neurosurgical Spine Institute
Beverly Hills, California, United States, 90048
2
Scripps Memorial Hospital Neurosurgery
La Jolla, California, United States, 92037
3
Northwestern Medical Facility
Chicago, Illinois, United States, 60611
4
Advanced Center for Orthopedics
Marquette, Michigan, United States, 49855